H. 12 de Octubre

Running trials

• Not yet recruiting

  Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia

  NCT07862946· Phase 2· Source

• Recruiting

  Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

  NCT07507760· Phase 2· Source

• Recruiting

  Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

  NCT07045909· Phase 2· Source

• Active, not recruiting

  Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  NCT05611931· Phase 3· Source

• Active, not recruiting

  National GMA Post-market Clinical Follow-up Study (GRACE)

  NCT05636709· Source

• Recruiting

  Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

  NCT04179929· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukemia1 recruiting
• Multiple myeloma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

  NCT05340413· Phase 2· Source